GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TriSalus Life Sciences
TriSalus Life Sciences develops methods for delivering drugs directly to tumors. Its stock price represents a venture capital bet on the success of its technology. The stock price reflects high volatility and dependence on clinical trial results.
Share prices of companies in the market segment - Cancer stomach
TriSalus Life Sciences develops innovative methods for delivering drugs directly to solid tumors, such as liver and pancreatic cancer. We've classified it in the "Gastric Cancer" segment, and the chart below shows how investors value companies working on breakthrough oncology technologies.
Broad Market Index - GURU.Markets
TriSalus Life Sciences develops innovative methods for delivering drugs directly to solid tumors, such as liver and pancreatic cancer. We've classified it in the "Gastric Cancer" segment, and the chart below shows how investors value companies working on breakthrough oncology technologies.
Change in the price of a company, segment, and market as a whole per day
TLSI - Daily change in the company's share price TriSalus Life Sciences
For TriSalus, an oncology company, change_co is a measure of reaction to clinical and regulatory news. Daily fluctuations reflect volatility associated with treatment development. This metric is a key element in analyzing young biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer stomach
TriSalus Life Sciences, Inc. is an oncology company. This chart illustrates the extreme volatility of the biotech sector. Comparison with TLSI's performance, with its unique drug delivery system, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
TriSalus is an oncology company developing a platform for delivering drugs directly to tumors. The biotech sector is extremely volatile, and TriSalus's story is a prime example. The chart below reflects the average fluctuations in this industry, providing context for the company's stock valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TriSalus Life Sciences
TriSalus Life Sciences' year-to-date performance reflects the development of an innovative platform for delivering drugs directly to liver and pancreatic tumors. Its 12-month market cap depends on progress in clinical trials, where it must demonstrate that its method can overcome barriers to effective immunotherapy.
Annual dynamics of market capitalization of the market segment - Cancer stomach
TriSalus Life Sciences, a company at the intersection of biotechnology and medical devices, develops innovative drug delivery methods for cancer treatment. Its performance will be highly volatile, reflecting investor confidence in its unique technology rather than overall sector trends.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
TriSalus is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its innovative cancer treatment platform. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TriSalus Life Sciences
As a company developing cancer therapies, TriSalus's performance will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news on the progress of clinical trials of its innovative drug delivery system directly to liver tumors.
Monthly dynamics of market capitalization of the market segment - Cancer stomach
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors to improve the effectiveness of therapy. The chart below reflects investor sentiment in the cancer treatment sector, where new delivery methods could dramatically improve outcomes.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
TriSalus Life Sciences is an oncology company developing methods for delivering drugs directly to tumors. It's a high-risk biotech play. Its stock performance depends entirely on progress in clinical trials and partnerships and has no correlation to overall market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TriSalus Life Sciences
Shares of TriSalus Life Sciences, a company developing methods for delivering drugs directly to tumors, are extremely volatile. Weekly price movements reflect news about clinical trials of their technology and partnerships with pharmaceutical companies. The chart below shows how short-term developments in innovative oncology impact the company's valuation.
Weekly dynamics of market capitalization of the market segment - Cancer stomach
How unique is TriSalus Life Sciences' performance in the biotech sector? This chart compares the weekly stock price movements of this drug delivery company with the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this cutting-edge field or reflect general sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
TriSalus Life Sciences develops methods for delivering drugs directly to tumors to improve treatment effectiveness. This chart compares its weekly price volatility with the market, showing how its stock, like other biotechs, is driven by clinical trial news rather than general trends.
Market capitalization of the company, segment and market as a whole
TLSI - Market capitalization of the company TriSalus Life Sciences
TriSalus Life Sciences' valuation chart is a bet on its innovative platform for delivering anti-cancer drugs directly to solid tumors, particularly in the liver. The company's clinical-stage market cap reflects hopes for improved therapy efficacy. Its dynamics illustrate the risks and potential of this new treatment method.
TLSI - Share of the company's market capitalization TriSalus Life Sciences within the market segment - Cancer stomach
TriSalus Life Sciences aims to gain market share by improving drug delivery directly to liver and pancreatic tumors. Its market cap reflects the potential of its technology to improve the effectiveness of immunotherapy in treating these hard-to-treat cancers.
Market capitalization of the market segment - Cancer stomach
This chart shows the combined market capitalization of biotech companies developing local drug delivery systems for tumors. TriSalus Life Sciences is an innovator in this niche. The dynamics in the chart reflect the hopes associated with increasing the effectiveness and reducing the toxicity of chemotherapy.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the hope for a new treatment for hard-to-reach tumors. TriSalus Life Sciences' market cap reflects its belief in its technology for delivering drugs directly to the liver and pancreas. The line shows how oncology innovations are competing for their share of global healthcare.
Book value capitalization of the company, segment and market as a whole
TLSI - Book value capitalization of the company TriSalus Life Sciences
TriSalus Life Sciences' book value represents its scientific and technological capital. The chart below reflects the valuation of its patents for its tumor-targeting drug delivery platform and its immunotherapy pipeline. The pipeline's growth reflects investments in developing a comprehensive approach to cancer treatment.
TLSI - Share of the company's book capitalization TriSalus Life Sciences within the market segment - Cancer stomach
TriSalus's tangible assets are not massive factories, but rather R&D centers and manufacturing facilities for its innovative drug delivery system directly to tumors. The chart reflects its share of this high-tech medical infrastructure, which could improve the effectiveness of cancer treatment.
Market segment balance sheet capitalization - Cancer stomach
Below you can see the overall book value of the biotech sector. Against this backdrop, TriSalus, which develops methods for delivering drugs directly to tumors, is capital-intensive in its niche. Its business requires the production of complex medical devices, making it heavier than pure R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
TriSalus Life Sciences develops methods for delivering drugs directly to liver and pancreatic tumors. The company's assets are patents for its devices and therapeutic programs. Their balance sheet is the cost of the "targeting system," which enables targeted disease attack in the body.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TriSalus Life Sciences
TriSalus's balance sheet is made up of its cash and patents. Its market capitalization is a bet on its tumor drug delivery technology. The MvsBCap_Co chart shows the gap between its modest assets and the high hopes that its "targeting system" will transform cancer treatment.
Market to book capitalization ratio in a market segment - Cancer stomach
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. Its value lies in its unique technology. The chart shows how the market perceives its potential to make treatment for these hard-to-treat cancers more effective.
Market to book capitalization ratio for the market as a whole
TriSalus Life Sciences develops methods for delivering drugs directly to liver and pancreatic tumors to improve the effectiveness of therapy. The company's value lies in its unique medical technology. This chart helps explain why the medical technology sector often trades at a premium to its book value, reflecting its belief in innovation.
Debts of the company, segment and market as a whole
TLSI - Company debts TriSalus Life Sciences
TriSalus Life Sciences, a biopharmaceutical company developing methods for delivering drugs directly to tumors, is using debt to advance its unique technology. This chart shows how the company is raising capital for clinical trials of its platform. In this industry, debt is an investment in improving the effectiveness of cancer treatment.
Market segment debts - Cancer stomach
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors to make therapy more effective. This is an innovative approach in oncology. This chart shows how the medical technology company is funding its clinical trials and the development of its unique platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TriSalus Life Sciences
TriSalus Life Sciences develops methods for delivering drugs directly to tumors. This chart shows the company's reliance on debt to finance its unique medical technologies. For a company at the intersection of oncology and medical devices, high debt is a bet on clinical and commercial success, which comes with very high risks.
Market segment debt to market segment book capitalization - Cancer stomach
TriSalus Life Sciences develops methods for delivering drugs directly to liver and pancreatic tumors. This is a highly specialized oncology technology. The chart shows how the company's debt load for funding development compares to the overall market capitalization and risks of the entire biotech sector.
Debt to book value of all companies in the market
TriSalus Life Sciences (TLSI) is developing targeted drug delivery methods directly to tumors, particularly the liver. This is an innovative approach in oncology. This chart shows the overall market debt burden. It clearly demonstrates why medical technology companies rely on investor capital rather than debt during clinical trials.
P/E of the company, segment and market as a whole
P/E - TriSalus Life Sciences
This metric for TriSalus Life Sciences, a company developing methods for delivering drugs directly to tumors, reflects hopes for a breakthrough in oncology. There is no price-to-earnings ratio. The company's valuation depends on the success of its technology in clinical trials and its potential to make existing cancer treatments more effective.
P/E of the market segment - Cancer stomach
This chart shows the average P/E for biotech companies. For TriSalus, with its drug delivery technology, it serves as a backdrop. It reflects the overall level of optimism in oncology, providing context for TriSalus's valuation, which is a bet that its technology will improve the effectiveness of existing treatments.
P/E of the market as a whole
TriSalus Life Sciences develops treatments for liver and pancreatic cancer. The company combines its tumor-targeting drug delivery platform with immunotherapy drugs. This risk appetite chart helps understand how investors evaluate companies developing comprehensive cancer treatment approaches.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TriSalus Life Sciences
TriSalus Life Sciences is an oncology company developing methods for delivering drugs directly to liver and pancreatic tumors, as well as immunotherapeutic agents. This schedule reflects expectations for its comprehensive approach to treating hard-to-treat tumors. The assessment is contingent on the success of its delivery technology and clinical trials of therapeutic candidates.
%20P%2FE%20TriSalus%20Life%20Sciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TriSalus-Life-Sciences&v=1772653311824 "Chart of the company's future (projected) P/E TriSalus Life Sciences")
Future (projected) P/E of the market segment - Cancer stomach
TriSalus Life Sciences develops methods for delivering drugs directly to solid tumors, such as liver and pancreatic cancer. This chart reflects the company's long-term profitability expectations and demonstrates how highly the market values the potential of their technology to improve the effectiveness of existing cancer treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-stomach&v=1772653311837 "Future (projected) P/E graph of the market segment - Cancer stomach")
Future (projected) P/E of the market as a whole
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. The company's success depends on the clinical results of its technology. This market expectations chart reflects the overall investment climate in biotechnology. Market optimism facilitates raising capital for such breakthrough, yet risky, projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772653311841 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TriSalus Life Sciences
TriSalus Life Sciences is an oncology company developing methods for delivering drugs directly to tumors, particularly the liver and pancreas. This improves therapy effectiveness and reduces side effects. Financial results reflect the costs of clinical trials of this innovative technology.
Profit of companies in the market segment - Cancer stomach
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. This highly specialized technology is in the development stage. This graph for the oncology sector demonstrates how innovations in treatment methods, not just the drugs themselves, can dramatically change the outcomes and profitability of therapy in the future.
Overall market profit
TriSalus Life Sciences is an oncology company developing methods for delivering drugs directly to liver and pancreatic tumors. Its future depends on the clinical success of this innovative technology. Investors focus on medical data, not the economic indicators that shape the overall picture in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TriSalus Life Sciences
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. This schedule reflects analyst expectations, which hinge on the clinical success of its technology and its ability to improve the efficacy of existing oncology therapies. Partnerships with pharmaceutical companies are key.
%20profit%20of%20the%20company%20TriSalus%20Life%20Sciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TriSalus-Life-Sciences&v=1772653311923 "Graph of future (projected) profit of the company TriSalus Life Sciences")
Future (predicted) profit of companies in the market segment - Cancer stomach
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. This chart shows the revenue forecast for the gastrointestinal cancer treatment sector. It reflects expectations for breakthroughs in the treatment of hard-to-treat tumors. This background is important for assessing the potential of TriSalus's innovative drug delivery technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-stomach&v=1772653312000 "Graph of future (predicted) profits of companies in a market segment - Cancer stomach")
Future (predicted) profit of the market as a whole
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. As a development-stage company, it relies on research and investment. The overall economic climate, as illustrated here, influences the availability of capital for the biotech sector and the willingness of investors to fund highly specialized medical projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772653312016 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TriSalus Life Sciences
TriSalus Life Sciences is an oncology company developing methods for delivering drugs directly to liver and pancreatic tumors to improve the effectiveness of therapy. This chart shows how investors view its technology platform, which could improve treatment outcomes for difficult-to-treat cancers.
P/S market segment - Cancer stomach
TriSalus Life Sciences is an oncology company developing treatments for solid tumors, particularly liver and pancreatic cancer. Its approach combines its proprietary tumor-delivery technology with immunotherapy. This chart shows the average valuation in the sector, helping to understand how the market views this innovative therapeutic platform.
P/S of the market as a whole
TriSalus Life Sciences is an oncology company developing a comprehensive approach to treating solid tumors, combining drug delivery directly to the tumor with immune system activation. This market valuation chart helps understand the premium investors are paying for the biotech's potentially breakthrough, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TriSalus Life Sciences
TriSalus Life Sciences develops methods for delivering drugs directly to liver and pancreatic tumors. As a clinical-stage company, it is valued based on its future prospects. This chart reflects investor expectations that its technology will improve cancer treatment efficacy and be commercially successful.
%20P%2FS%20TriSalus%20Life%20Sciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TriSalus-Life-Sciences&v=1772653312204 "The graph of the company's future (projected) P/S TriSalus Life Sciences")
Future (projected) P/S of the market segment - Cancer stomach
TriSalus Life Sciences is an oncology company developing methods for localized drug delivery directly to tumors. This chart compares market expectations for its future revenue with other companies working in the gastric cancer field. The valuation reflects investor confidence in its technology platform for improving the effectiveness of therapy.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-stomach&v=1772653312231 "Future (projected) P/S market segment graph - Cancer stomach")
Future (projected) P/S of the market as a whole
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. This is a highly specialized but important area of oncology. Market optimism, evident in this chart, is helping companies like these raise capital for clinical trials that could significantly improve patient outcomes.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772653312263 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TriSalus Life Sciences
TriSalus Life Sciences is an oncology company developing methods for delivering drugs directly to tumors, particularly in the liver and pancreas. Currently in the commercialization stage, its revenue is generated from sales of its medical devices. The chart shows initial sales and the adoption of its innovative technology by cancer centers.
Sales of companies in the market segment - Cancer stomach
TriSalus Life Sciences develops innovative methods for delivering drugs directly to liver and pancreatic tumors. The company's technology aims to overcome intratumoral barriers to improve therapeutic efficacy. This chart shows investor interest in new platforms for treating difficult-to-treat cancers, where TriSalus offers a unique approach.
Overall market sales
TriSalus Life Sciences is developing methods for delivering drugs directly to tumors. This is a highly specialized medical technology, the prospects of which depend on the results of clinical trials. The economic situation reflected in this chart influences the overall investment climate in the biotech sector, which is important for the financing of such companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TriSalus Life Sciences
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors to improve the effectiveness of therapy. The company is in the clinical stage. This timeline reflects analysts' expectations for the commercial potential of this technology if it proves effective in treating difficult-to-treat cancers.
%20sales%20of%20the%20company%20TriSalus%20Life%20Sciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TriSalus-Life-Sciences&v=1772653312371 "Schedule of future (projected) sales of the company TriSalus Life Sciences")
Future (projected) sales of companies in the market segment - Cancer stomach
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. This chart shows the overall outlook for the oncology sector. It allows one to assess whether the company's innovative approach can improve the effectiveness of existing cancer treatments and carve out a niche in the complex oncology technology market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-stomach&v=1772653312534 "Schedule of future (projected) sales of companies in the market segment - Cancer stomach")
Future (projected) sales of the market as a whole
TriSalus Life Sciences is developing methods for delivering drugs directly to liver and pancreatic tumors. This chart, reflecting its investments in oncology, is important to the company. Investor confidence and the availability of capital in the sector allow TriSalus to continue clinical trials and develop its innovative therapeutic platform.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772653312603 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TriSalus Life Sciences
TriSalus Life Sciences is an oncology company developing treatments for liver and pancreatic cancer. Its approach combines an innovative drug delivery device and immunotherapy. This schedule reflects a phase of intensive investment in clinical trials to validate the efficacy of its unique therapeutic platform.
Market segment marginality - Cancer stomach
TriSalus Life Sciences develops methods for delivering drugs directly to solid tumors, such as liver and pancreatic cancer, to improve therapy efficacy. This is an innovative approach in oncology. This chart reflects the level of investment in their unique technology platform, which straddles the intersection of medical devices and pharmaceuticals.
Market marginality as a whole
TriSalus Life Sciences develops methods for delivering drugs directly to liver and pancreatic tumors. The overall profitability picture is irrelevant for them. Their business combines medical devices and drug development. Success depends on whether their technology proves capable of improving the effectiveness of chemotherapy.
Employees in the company, segment and market as a whole
Number of employees in the company TriSalus Life Sciences
TriSalus Life Sciences is an oncology company developing a comprehensive approach to treating liver and pancreatic cancer. This graphic shows the team working on both the drug delivery device and the drugs themselves. The scale of the team reflects the complexity of this integrated strategy.
Share of the company's employees TriSalus Life Sciences within the market segment - Cancer stomach
TriSalus Life Sciences develops methods for delivering drugs directly to solid tumors such as liver and pancreatic cancer. This chart shows its market share in a narrow oncology niche. It reflects the company's focus and the team's dedication to developing technologies that can improve the treatment of hard-to-treat tumors.
Number of employees in the market segment - Cancer stomach
TriSalus Life Sciences develops methods for delivering drugs directly to liver and pancreatic tumors to improve treatment effectiveness. This chart shows employment in the oncology technology sector. The growing number of engineers and clinicians reflects progress in the development of innovative medical devices that can improve cancer treatment outcomes.
Number of employees in the market as a whole
TriSalus Life Sciences develops innovative methods for delivering drugs directly to liver and pancreatic tumors, increasing the effectiveness of therapy. This is cutting-edge oncology. In this graph showing overall employment, companies like TriSalus represent the knowledge-intensive medical sector, creating jobs for highly qualified engineers, scientists, and physicians.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TriSalus Life Sciences (TLSI)
TriSalus Life Sciences, Inc. is an oncology company developing methods for delivering drugs directly to tumors. Its business combines medical devices and drug development. This chart shows a high market capitalization per employee, as investors evaluate the potential of their unique technology to transform cancer treatment. Value is generated by a small team of scientists and engineers.
%20of%20the%20company%20TriSalus%20Life%20Sciences%20(TLSI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TriSalus-Life-Sciences-TLSI&v=1772653312966 "Chart of market capitalization per employee (in thousands of dollars) of the company TriSalus Life Sciences (TLSI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer stomach
TriSalus Life Sciences develops methods for delivering drugs directly to liver and pancreatic tumors. This is a highly specialized medical technology. The chart shows how the market perceives the potential of this innovative platform for improving cancer treatment outcomes and the value it attributes to its small but highly skilled team.
%20by%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-stomach&v=1772653313003 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer stomach")
Market capitalization per employee (in thousands of dollars) for the overall market
TriSalus Life Sciences develops methods for delivering drugs directly to liver and pancreatic tumors. This is a highly specialized medical technology. This chart reflects how the market perceives the potential of their innovative approach to improve the treatment of hard-to-treat cancers.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772653313035 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TriSalus Life Sciences (TLSI)
TriSalus Life Sciences (TLSI) is an oncology company developing methods for delivering drugs directly to tumors (liver, pancreas). It's a medtech and R&D company. This chart shows the "cost" of developing this niche technology. It measures the negative profit (expense) for each employee involved in clinical trials.
%20Chart%20TriSalus%20Life%20Sciences%20(TLSI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TriSalus-Life-Sciences-TLSI&v=1772653313064 "Company Profit Per Employee (in thousands of dollars) Chart TriSalus Life Sciences (TLSI)")
Profit per employee (in thousands of dollars) in the market segment - Cancer stomach
TriSalus Life Sciences develops both immunotherapy drugs and devices for delivering them directly to liver tumors. This hybrid approach is their signature. This graph demonstrates the benchmark for biotech staff efficiency. It's important for assessing how effectively the TriSalus team is utilizing their unique approach.
%20in%20the%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-stomach&v=1772653313091 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer stomach")
Profit per employee (in thousands of dollars) for the market as a whole
TriSalus Life Sciences is a company at the intersection of oncology and medical technology. They have developed a specialized system (TriSalus Delivery System) for delivering drugs directly to liver and pancreatic tumors. It's a "razor and blade" model. This graph shows how effectively their team (R&D and sales) is promoting this two-component treatment system.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772653313101 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TriSalus Life Sciences (TLSI)
TriSalus Life Sciences is an oncology company developing methods for delivering drugs directly to liver and pancreatic tumors. This chart reflects its clinical status. Low revenue per employee is typical for companies whose technology and therapeutic candidates are still in clinical trials and have not yet reached the commercial market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TriSalus-Life-Sciences-TLSI&v=1772653313109 "Sales chart per company employee TriSalus Life Sciences (TLSI)")
Sales per employee in the market segment - Cancer stomach
TriSalus Life Sciences (TLSI) is an oncology company developing both liver and pancreatic cancer treatments and devices for delivering these drugs directly to tumors. This chart shows how much revenue (from partnerships or device sales) each employee generates. It's an indicator of the effectiveness of their hybrid (pharma and medical technology) business model.
Sales per employee for the market as a whole
TriSalus Life Sciences is an oncology company focused on two areas: developing immunotherapy and creating an innovative drug delivery system for tumors. This graph shows their early stages: the company is beginning to generate initial revenue from its devices, while its R&D staff is working on therapeutics that are not yet profitable.
Short shares by company, segment and market as a whole
Shares shorted by company TriSalus Life Sciences (TLSI)
TriSalus Life Sciences is a company developing methods for delivering drugs (immunotherapy) directly to liver and pancreatic tumors. This chart shows bearish bets. Shorting clinical-stage biotechs is a bet that their technology will not prove effective or safe in trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TriSalus-Life-Sciences-TLSI&v=1772653313176 "Short Shares Chart for the Company TriSalus Life Sciences (TLSI)")
Shares shorted by market segment - Cancer stomach
TriSalus Life Sciences (TLSI) is a company developing methods for delivering drugs (via an infusion system) directly to solid tumors (liver, pancreas). This chart shows the odds against the MedTech sector. The rising odds against the industry reflect investor skepticism about the commercialization of this niche technology and concerns about funding.
Shares shorted by the overall market
TriSalus Life Sciences (TLSI) is a company focused on treating liver and pancreatic cancer, combining drug delivery devices and therapeutics. It's a risky biotech. This market pessimism chart shows when investors are fleeing speculative stories. TLSI shares, dependent on R&D, are under intense pressure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TriSalus Life Sciences (TLSI)
TriSalus Life Sciences is a clinical-stage biotech. Shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general investor risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TriSalus-Life-Sciences-TLSI&v=1772653313315 "RSI 14 indicator chart for the company's stock TriSalus Life Sciences (TLSI)")
RSI 14 Market Segment - Cancer stomach
TriSalus Life Sciences is tackling hard-to-treat tumors (liver, pancreas) using its unique drug delivery technology (PEDD) to enhance the effectiveness of chemotherapy. This chart shows the overall "temperature" in the volatile oncology biotech sector. It helps separate the TLSI dynamics from the general "hype" or "disappointment" that has engulfed this niche.
RSI 14 for the overall market
TriSalus Life Sciences (TLSI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TLSI (TriSalus Life Sciences)
TriSalus Life Sciences develops drug delivery systems (infusion systems) directly to liver and pancreatic tumors. This chart shows the average target price. Analysts' estimates are based on their technology's potential to improve chemotherapy efficacy and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TLSI-TriSalus-Life-Sciences&v=1772653313421 "A chart showing analyst consensus forecasts for the expected stock price. TLSI (TriSalus Life Sciences)")
The difference between the consensus estimate and the actual stock price TLSI (TriSalus Life Sciences)
TriSalus (TLSI) is an oncology company that has developed a smart system (Pressure-Enabled Drug Delivery) for delivering chemotherapy directly to liver and pancreatic tumors. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their drug delivery technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TLSI-TriSalus-Life-Sciences&v=1772653313492 "A chart showing the difference between the consensus forecast and the actual stock price. TLSI (TriSalus Life Sciences)")
Analyst consensus forecast for stock prices by market segment - Cancer stomach
TriSalus Life Sciences (TLSI) is an oncology company developing a new method for delivering chemotherapy (SD-Criterion) directly to liver and pancreatic tumors. This chart shows general expectations for the oncology sector. It reflects whether experts believe a breakthrough in the treatment of these most deadly cancers is possible.
Analysts' consensus forecast for the overall market share price
TriSalus Life Sciences is an oncology company developing methods for delivering drugs directly to liver and pancreatic tumors to overcome tumor resistance. This chart shows the overall "risk appetite." For TriSalus, a company with an innovative delivery platform, overall market optimism (the rising chart) is important for funding clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TriSalus Life Sciences
TriSalus Life Sciences is a MedTech company aiming to defeat liver and pancreatic cancer by hacking drug delivery. Their technology (Pressure-Enabled Drug Delivery) is a smart catheter that delivers chemotherapy to tumors under pressure, overcoming their defenses. This graph is a summary of their R&D, reflecting their progress in clinical trials and their belief in their innovative delivery method.
AKIMA Market Segment Index - Cancer stomach
TriSalus Life Sciences develops methods for delivering drugs directly to tumors, particularly the liver, to treat cancer. This chart shows the average index for the oncology sector. It helps investors understand how promising TriSalus's innovative approach to therapy delivery is compared to the industry average.
The AKIM Index for the overall market
TriSalus Life Sciences is a MedTech company combining drug delivery technology (pressurized infusion) with immunotherapy for the treatment of liver and pancreatic cancer. This chart, reflecting the market average, provides context. It helps assess how this hybrid device-drug combination compares to overall macroeconomic trends.
